Tarix Orphan is a private biopharmaceutical company headquartered in Cambridge, MA. Tarix Orphan is developing TXA127 for rare neuromuscular and connective tissue diseases. TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 has been effective in animal models of Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy MDC1A, Marfan syndrome, and ALS. Tarix Orphan has broad IP protection for TXA127 and Orphan Drug Designations (ODDs) have been granted for DMD and LGMD in the U.S., and for DMD in Europe. Tarix Orphan aims to initiate a clinical trials for both DMD and MDC1A in early 2016 and has an active IND for a Phase II trial in DMD, as well as Fast Track designation for DMD.